cell
coat
complex
carbohydr
call
glycan
form
layer
known
glycocalyx
rang
nm
glycan
present
mani
differ
molecular
form
includ
glycoprotein
proteoglycan
glycolipid
glycophosphatidylinositollink
protein
broad
divers
origin
assembl
monosaccharid
build
block
link
variou
posit
pyranos
furanos
ring
ring
establish
sever
linkag
give
rise
branch
structur
final
structur
complex
glycan
increas
possibl
anomer
centr
dens
structur
inform
decod
carbohydratebind
protein
involv
import
physiolog
pathophysiolog
event
need
integr
approach
deciph
relationship
sar
glycan
protein
receptor
led
establish
interdisciplinari
collabor
effort
unit
state
consortium
function
glycom
see
inform
europ
eurocarb
see
inform
japan
human
diseas
glycomicsproteom
initi
see
inform
current
carbohydratebind
protein
identifi
bind
specif
mani
elucid
other
screen
larg
glycoarray
determin
glycanbind
epitop
discoveri
led
renaiss
glycobiolog
also
provid
continu
suppli
carbohydraterel
target
structurebas
design
new
chemic
entiti
mimic
bioactiv
carbohydr
form
novel
class
therapeut
carbohydr
carbohydratederiv
drug
although
carbohydr
play
import
part
vast
array
biolog
process
carbohydr
carbohydratederiv
drug
cover
limit
area
world
therapeut
fig
mani
pathophysiolog
import
interact
yet
exploit
sourc
new
drug
target
one
reason
might
pharmacokinet
drawback
inher
link
carbohydr
result
high
polar
unabl
cross
passiv
enterocyt
layer
small
intestin
prerequisit
oral
avail
addit
system
avail
parenter
administr
carbohydr
suffer
fast
renal
excret
interact
blood
plasma
compon
possibl
plasma
halflif
requir
success
therapeut
applic
achiev
promin
exampl
lowmolecularweight
heparin
deriv
anim
tissu
arixtra
glaxosmithklin
use
anticoagul
case
inhibit
brush
border
small
intestin
treatment
diabet
basenglustatvolix
takeda
glyset
pfizer
glucobayprandaseprecos
bayer
inhibit
viral
neuraminidas
pharyng
mucosa
relenza
glaxosmithklin
oral
avail
requir
paradigm
glycomimet
drug
classic
sens
oseltamivir
tamiflu
gileadroch
start
carbohydr
lead
drug
like
achiev
systemat
elimin
polar
group
metabol
soft
spot
requir
affin
final
design
prodrug
oral
avail
becam
glycodrug
preclin
clinic
evalu
carbohydratebind
protein
broadli
classifi
sulphat
glycosaminoglycan
sgag
bind
two
categori
lectin
present
vertebr
famili
intracellular
lectin
exampl
calnexin
ltype
ptype
lectin
bind
core
oligosaccharid
structur
involv
glycoprotein
process
qualiti
control
famili
extracellular
lectin
exampl
galectin
ctype
ityp
rtype
lectin
recogn
termin
carbohydr
epitop
cell
pathogen
extracellular
lectin
account
molecular
target
investig
current
drug
discoveri
programm
contrast
sgagbind
protein
heterogen
difficult
abil
recogn
sgag
aris
cluster
cation
amino
acid
unrel
protein
confer
abil
recogn
anion
structur
motif
extend
sgag
chain
typic
variou
sgagbind
protein
interact
sgag
differ
affin
sgag
sequenc
exclus
recogn
singl
sgagbind
protein
present
promis
drug
candid
lectin
famili
selectin
dendrit
cellspecif
nonintegrin
dcsign
also
known
ctype
lectin
famili
myelinassoci
glycoprotein
mag
also
known
sialic
acidbind
immunoglobulinlik
lectin
siglec
exampl
ityp
lectin
pai
galactophil
lectin
pail
fucosebind
lectin
paiil
minor
compon
type
fimbria
fimh
repres
bacteri
lectin
ctype
lectin
hallmark
ctype
lectin
involv
bind
glycan
carbohydr
recognit
domain
crd
wide
rang
biolog
function
intercellular
adhes
serum
glycoprotein
remov
pathogen
recognit
selectin
perhap
intens
studi
mammalian
carbohydratebind
protein
first
discov
ref
function
adhes
molecul
well
famili
consist
three
member
eselectin
also
known
pselectin
also
known
lselectin
also
known
compos
crd
epiderm
growth
factor
egf
domain
variou
short
complementlik
consensu
repeat
singl
transmembran
domain
intracellular
tail
although
carbohydr
bind
receptor
site
within
crd
neighbour
egf
domain
influenc
bind
affin
three
selectin
overlap
distinct
express
pattern
tempor
spatial
eselectin
express
endotheli
cell
de
novo
protein
synthesi
hour
stimul
inflammatori
mediat
interleukin
tumour
necrosi
pselectin
express
activ
platelet
also
store
bodi
endotheli
cell
fuse
cell
surfac
activ
lead
express
pselectin
within
minut
lselectin
constitut
express
leukocyt
play
major
part
home
traffick
lymphocyt
blood
lymphat
system
three
selectin
bind
common
carbohydr
domain
share
sialyl
leax
sialyl
lewisa
slea
sialyl
lewisx
slex
interestingli
carbohydr
sequenc
origin
discov
cancerassoci
prognost
indic
metastat
tumour
cell
coat
carbohydr
chain
recogn
migrat
leukocyt
allow
escap
bloodstream
metastas
organ
tissu
lymph
node
bone
function
bind
sialyl
leax
vivo
p
lselectin
requir
addit
interact
neg
charg
sulphat
group
either
carbohydr
chain
adjac
peptid
sequenc
eselectin
requir
function
bind
sialyl
leax
involv
neg
charg
group
sulphat
carboxyl
bind
l
pselectin
led
one
major
pitfal
design
smallmolecul
inhibitor
selectin
wide
rang
structur
divers
neg
charg
molecul
report
bind
p
lselectin
includ
sulphat
chondroitin
dermatan
tyrosin
sulphat
hyaluron
rang
molecul
suggest
inhibitori
activ
due
nonspecif
negativecharg
interact
fact
cautionari
describ
potent
pselectin
activ
found
trace
contamin
polyanion
ion
exchang
media
use
prepar
sampl
thu
specif
smallmolecul
highli
charg
selectin
antagonist
inhibit
p
l
eselectin
must
care
evalu
diseas
cell
adhes
extravas
cell
bloodstream
migrat
specif
lymphocyt
implic
patholog
selectin
present
attract
therapeut
target
exampl
e
pselectin
shown
mediat
acut
adhes
aggreg
leukocyt
erythrocyt
vasoocclus
crisi
mous
model
sickl
cell
furthermor
aberr
extravas
cell
bloodstream
hallmark
mani
inflammatori
diseas
asthma
coliti
arthriti
psoriasi
cancer
tumour
cell
extravas
bloodstream
use
selectin
pathway
metastas
mani
solid
tumour
adenocarcinoma
cancer
express
high
level
slex
slea
express
selectin
ligand
tumour
cell
patient
gastric
colon
significantli
correl
poor
cimetidin
tagamet
glaxosmithklin
histamin
receptor
antagonist
also
suppress
vascular
express
eselectin
markedli
specif
improv
surviv
highrisk
patient
identifi
tumour
express
slea
slex
ref
support
use
selectin
therapeut
target
cancer
selectin
ligand
also
report
play
key
part
dissemin
haematolog
home
leukaem
stem
cell
microdomain
within
bone
eselectin
constitut
express
bone
bind
carbohydr
ligand
found
leukaem
stem
cell
adher
microdomain
bone
marrow
leukaem
cell
becom
quiescent
less
suscept
kill
antiprolif
chemotherapi
drug
cytosin
potent
selectin
antagonist
present
new
therapeut
opportun
treat
diseas
prevent
sequestr
leukaem
cell
bone
marrow
keep
circul
combin
therapi
selectin
antagonist
like
make
cell
suscept
chemotherapi
exampl
glycomimet
smallmolecul
antagonist
selectin
present
tabl
dcsign
mucos
surfac
present
barrier
environ
potenti
suscept
infect
migrat
dendrit
cell
guard
mucos
surfac
captur
microorgan
present
process
antigen
activ
cell
therebi
induc
immun
respons
invad
pathogen
screen
librari
dendrit
cellspecif
monoclon
antibodi
inhibit
bind
intercellular
adhes
molecul
adhes
molecul
activ
cell
singl
cell
surfac
protein
discov
aminoacid
sequenc
dcsign
ident
previous
describ
hiv
glycoprotein
bind
ctype
dcsign
express
patrol
dendrit
cell
mucosa
bind
carbohydr
structur
protein
coat
hiv
initi
entri
port
hiv
host
hiv
particl
bound
dcsign
surfac
dendrit
cell
protect
destruct
blood
migrat
lymph
node
transinfect
cell
ccchemokin
receptor
complex
cell
bind
specif
dcsign
fucos
mannos
residu
higher
affin
specif
fucos
linkag
leaxtyp
oligosaccharid
structur
format
activ
structur
bind
dcsign
occur
addit
hiv
variou
pathogen
hepat
c
dengu
ebola
marburg
coronaviru
caus
sever
acut
respiratori
syndrom
well
bacteria
mycobacterium
tuberculosi
helicobact
pylor
yeast
candida
albican
exploit
dcsign
infect
host
recent
even
parasit
leishmani
schistosoma
manson
also
shown
bind
dcsign
fact
differ
pathogen
capit
infect
strategi
make
dcsign
interest
target
therapeut
intervent
studi
bind
transfer
hiv
human
rectal
mucosa
cell
bound
viru
bound
cell
express
dcsign
although
cell
repres
total
mucos
mononuclear
cell
furthermor
dcsignspecif
antibodi
block
hiv
studi
shown
multival
glycoconjug
lewisx
dmannos
prevent
attach
ebola
herp
viru
dendrit
cell
dcsign
thu
prevent
subsequ
infect
immun
glycomimet
compound
inhibit
dcsign
base
two
lead
structur
first
highmannos
oligosaccharid
second
lfucos
part
lewi
determin
synthes
pathogen
camouflag
appear
host
tissu
improv
affin
pharmacokinet
properti
natur
occur
antagonist
glycomimet
type
ligand
synthes
highdens
array
unbranch
mantermin
oligosaccharid
bind
dcsign
almost
effect
entir
oligosaccharid
ref
therefor
nonreduc
end
man
fragment
suggest
play
crucial
part
dcsign
recognit
mimic
one
hexos
moieti
replac
cyclohexanediol
deriv
lead
compound
fig
threefold
greater
affin
dcsign
halfmaxim
inhibitori
concentr
mm
mm
respect
furthermor
infect
studi
use
vivo
model
ebola
infect
glycomimet
compound
inhibit
infect
dcsignexpress
jurkat
cell
effici
correspond
natur
disaccharid
although
inhibitori
concentr
experi
millimolar
rang
compound
might
use
prepar
highaffin
multival
antagonist
approach
encourag
strong
inhibitori
effect
multival
antagonist
dcsign
bind
observ
dendrit
mannos
oligolysinebas
oligosaccharid
similarli
link
acid
compound
mimic
lewisx
trisaccharid
inhibit
dcsign
twofold
greater
potenc
mm
mm
respect
bind
affin
weak
compound
therapeut
promis
howev
oligosaccharid
display
larg
multival
dendrim
activ
greatli
improv
biolog
activ
shown
although
larg
multival
present
carbohydr
mimic
thereof
rel
simpl
mean
increas
activ
pose
pharmaceut
challeng
term
rout
administr
possibl
side
effect
unwant
immun
respons
classic
approach
discov
dcsign
antagonist
success
demonstr
screen
larg
librari
small
molecul
autom
assay
format
screen
compound
hit
valu
low
micromolar
rang
identifi
compound
compound
ref
interestingli
structur
hit
bear
resembl
nativ
carbohydr
ligand
oligomannos
lewi
epitop
contain
function
group
interact
crd
inhibitori
activ
could
caus
bind
domain
dcsign
lead
alloster
effect
ityp
lectin
ityp
lectin
famili
carbohydratebind
protein
immunoglobulin
superfamili
includ
siglec
function
cell
signal
coreceptor
primarili
express
leukocyt
mediat
acquir
innat
immun
function
cytoplasm
domain
siglec
contain
immunoreceptor
tyrosinebas
inhibitori
motif
characterist
accessori
protein
regul
transmembran
signal
endocytosi
cell
surfac
receptor
protein
divers
specif
sialosid
ligand
variabl
cytoplasm
regulatori
element
enabl
siglec
carri
uniqu
role
cell
surfac
siglec
broadli
divid
evolutionarili
conserv
group
siglec
also
known
sialoadhesin
siglec
also
known
siglec
also
known
mag
siglec
group
siglec
siglec
evolutionarili
conserv
group
show
select
bind
properti
siglec
mag
preferenti
bind
link
nacetylneuramin
acid
siglec
highli
specif
link
contrast
member
siglec
group
promiscu
bind
often
recogn
one
present
comprehens
character
siglec
siglec
regulatori
protein
prevent
overactiv
immun
system
develop
autoimmun
diseas
mag
protein
block
regener
central
nervou
system
cn
mag
unlik
peripher
nervou
system
pn
injur
adult
cn
inher
lack
capac
axon
regener
although
neurit
outgrowth
possibl
princip
block
inhibitor
protein
express
residu
myelin
astrocyt
recruit
site
injuri
date
three
major
inhibitor
protein
identifi
reticulon
also
known
nogo
myelin
oligodendrocyt
glycoprotein
mog
three
protein
bind
activ
receptor
locat
surfac
neuron
lead
format
complex
nerv
growth
factor
receptor
ngfr
also
known
activ
rhoassoci
coil
coilcontain
protein
kinas
cascad
result
growth
cone
inhibitori
cascad
also
trigger
complex
form
mag
brain
gangliosid
especi
although
exact
biolog
role
interact
yet
resolv
system
inhibit
axon
regener
mag
could
complet
revers
sialidas
treatment
suggest
sialid
glycan
main
axon
ligand
sar
reveal
termin
tetrasaccharid
epitop
galnac
show
superior
bind
mag
compar
termin
trisaccharid
epitop
present
refin
sar
profil
led
identif
mag
antagonist
improv
affin
least
case
remark
simpl
structur
fig
howev
owe
use
differ
assay
format
difficult
compar
report
affin
compound
variou
ligand
overal
start
lowaffin
tetrasaccharid
lead
structur
compound
ref
lowmolecularmass
mag
antagonist
nanomolar
affin
excel
stabil
spinal
cord
fluid
identifi
mesch
moser
vedani
b
cut
wittwer
h
shelk
strasser
schwardt
kelm
b
ernst
unpublish
observ
high
correl
degre
neurit
outgrowth
bind
affin
antagonist
valid
mag
therapeut
target
suggest
potent
glycan
inhibitor
mag
potenti
enhanc
axon
bacteri
viral
lectin
colon
subsequ
develop
infecti
diseas
enter
oral
respiratori
bacteria
requir
adhes
host
tissu
grant
substanti
greater
resist
clearanc
kill
immun
factor
bacteriolyt
enzym
antibiot
addit
bacteria
better
abl
acquir
nutrient
enhanc
abil
surviv
infect
host
therefor
antiadhes
drug
prevent
adhes
pathogen
host
tissu
may
offer
novel
strategi
fight
infecti
alarm
increas
drugresist
bacteri
pathogen
make
search
new
approach
fight
bacteri
infect
antiadhes
agent
bactericid
less
like
promot
propag
resist
strain
bactericid
agent
antibiot
carbohydr
epitop
surfac
host
cell
use
bacteria
virus
colon
infect
tabl
start
point
search
glycomimet
entri
inhibitor
challeng
antiadhes
therapi
pathogen
possess
gene
encod
sever
type
adhesin
infect
process
may
express
one
adhesin
glycomimet
antagonist
design
inhibit
multipl
adhesin
feasibl
develop
exampl
describ
pseudomona
aeruginosa
p
aeruginosa
virul
factor
pail
paiil
p
aeruginosa
part
normal
flora
healthi
adult
becom
deadli
pathogen
individu
immunocompromis
patient
cystic
fibrosi
hospit
critic
ill
patient
increas
percentag
p
aeruginosa
infect
antibiot
resist
adhes
host
cell
pathogen
express
lectin
pail
lectin
virul
factor
quorum
sens
control
cytotox
primari
epitheli
cell
low
concentr
inhibit
ciliari
beat
epitheli
cell
explant
nasal
inhibit
complet
revers
treatment
carbohydr
ligand
lectin
thu
hour
addit
fucos
ciliari
beat
return
normal
pail
paiil
tetramer
lectin
requir
carbohydr
bind
crystal
structur
lectin
complex
carbohydr
ligand
resolv
fig
pail
preferenti
bind
termin
dgalactos
presenc
one
ion
wherea
paiil
bind
unusu
strong
micromolar
affin
lfucos
requir
two
pail
paiil
solubl
intracellular
lectin
howev
releas
cell
lectin
caus
bacteria
adher
host
tissu
process
revers
incub
dgalactos
dmannos
nativ
carbohydr
inhibitor
pail
paiil
dgalactos
lfucos
success
use
treat
tobramycinresist
p
aeruginosa
infect
case
combin
therapi
tobramycin
dgalactos
lfucos
inhibit
virul
factor
pail
paiil
cure
infant
system
pulmonari
infect
determin
microbiolog
test
screen
glycan
array
consortium
function
glycom
reveal
lewisa
trisaccharid
glcnac
highaffin
ligand
dissoc
constant
reduc
complex
trisaccharid
antagonist
glycomimet
base
glcnac
disaccharid
exampl
antagonist
compound
synthes
titrat
calorimetri
experi
increas
entropi
cost
upon
bind
detect
result
higher
flexibl
glcnac
compar
lewisa
howev
addit
enthalp
interact
origin
network
hydrogen
bond
compens
entrop
simplif
paiil
antagonist
achiev
bear
heterocycl
substitu
aglycon
synthes
surprisingli
candid
exampl
compound
similar
potenc
lewisa
ref
oligoval
form
glcnac
epitop
compound
ref
exhibit
increas
activ
compar
monoval
form
howev
case
effect
modest
per
saccharid
basi
date
multival
explor
dendrim
present
lfucos
show
increas
affin
factor
per
saccharid
final
prevent
adhes
p
aeruginosa
mediat
simultan
pail
paiil
lectin
heterobifunct
ligand
present
dgalactos
lfucos
oligoval
array
compound
ref
smallmolecul
glycomimet
compound
ref
construct
studi
determin
efficaci
compound
mice
surgic
stress
hepatectomi
control
group
die
hour
acut
infect
p
aeruginosa
wherea
mice
treat
compound
fimh
urinari
tract
infect
uti
among
preval
inflammatori
diseas
caus
predomin
pathogen
uti
uropathogen
escherichia
coli
upec
caus
infect
otherwis
healthi
peopl
uncompl
uti
healthi
individu
uropathogen
origin
rectal
microbiota
enter
normal
steril
urinari
bladder
urethra
trigger
infect
cystiti
urinari
tract
bacteria
attach
urinari
tract
epithelium
fimbrial
adhes
molecul
avoid
host
defenc
mechan
bound
bacteria
presum
intern
activ
process
similar
uncompl
uti
effect
treat
oral
antibiot
fluoroquinolon
cotrimoxazol
amoxicillin
clavanul
depend
suscept
pathogen
involv
howev
recurr
infect
subsequ
antibiot
exposur
result
emerg
antimicrobi
resist
often
lead
treatment
failur
reduc
rang
therapeut
option
urgent
need
effici
costeffect
safe
nonantibiot
therapi
prevent
treat
uti
without
facilit
antimicrobi
resist
inhibit
type
fimbriaemedi
bacteri
attach
bladder
epithelium
promis
approach
achiev
studi
show
primari
bladder
cell
ligand
upec
attach
event
requir
highli
conserv
fimh
lectin
locat
tip
bacteri
fimbria
analysi
show
residu
fimh
mannos
bind
pocket
invari
across
upec
two
decad
ago
variou
aromat
antagon
type
fimbriaemedi
bacteri
adhes
identifi
two
approach
taken
improv
affin
ration
design
ligand
guid
inform
obtain
crystal
structur
fimh
multival
present
epitop
crystal
structur
fimh
receptorbind
domain
solv
ref
correspond
complex
ref
recent
becom
avail
despit
detail
knowledg
bind
event
attempt
translat
inform
lowmolecularmass
antagonist
select
monoval
fimh
antagonist
depict
fig
refer
compound
methyl
compound
bind
millimolar
potent
monoval
antagonist
report
far
compound
bind
nanomolar
report
affin
explain
basi
structur
crd
locat
tip
fimh
protein
fig
first
hydroxyl
group
posit
mannos
form
extend
hydrogen
bond
second
entranc
bind
site
form
two
tyrosin
one
isoleucin
socal
tyrosin
gate
support
hydrophob
aromat
aglycon
antagonist
occur
compound
exampl
establish
energet
favour
interact
tyrosin
gate
lead
substanti
improv
affin
enhanc
affin
achiev
use
oligoval
multival
fimh
antagonist
exampl
compound
solubl
fimh
antagonist
appli
prevent
bacteri
adhes
host
tissu
face
challeng
mechan
forc
result
fluid
flow
commonli
presum
durat
interact
shorten
shear
stress
howev
recent
discov
abil
e
coli
avoid
detach
dramat
increas
shear
consequ
shear
stressenhanc
adhes
e
coli
evad
detach
bodi
surfac
solubl
glycoprotein
peptid
ubiquit
bodi
fluid
exampl
glycoprotein
uromodulin
also
known
urinari
glycoprotein
bind
fimh
thought
function
bodi
defenc
e
coli
basi
thought
forceinduc
separ
fimh
mannos
ligand
caus
conform
chang
bind
pocket
lowaffin
highaffin
conform
instead
applic
competit
antagonist
alloster
antagonist
capabl
stabil
lowaffin
conform
might
lead
success
therapi
although
monoval
oligoval
antagonist
nanomolar
affin
report
data
avail
regard
pharmacokinet
properti
howev
treatment
uti
oral
bioavail
fast
renal
excret
reach
target
urinari
tract
prerequisit
therapeut
success
ration
design
challeng
lesson
learn
field
spawn
success
new
therapeut
exampl
monoclon
antibodi
year
effort
requir
understand
uniqu
challeng
inher
link
carbohydratederiv
drug
develop
basic
skill
specif
knowledg
move
excit
scientif
discoveri
develop
new
class
therapeut
although
anim
lectin
usual
show
high
degre
specif
glycan
structur
singlesit
bind
affin
typic
low
biolog
system
function
affin
often
attain
oligoval
present
crd
either
oligomer
protein
exampl
cholera
cluster
cell
surfac
exampl
asialoglycoprotein
addit
pharmacokinet
properti
carbohydr
hit
bioavail
plasma
halflif
typic
unsatisfactori
therapeut
applic
final
although
tremend
improv
novel
glycosyl
solidphas
becom
avail
oligosaccharid
still
manufactur
cumbersom
multistep
synthes
therefor
challeng
mimic
structur
inform
function
carbohydr
compound
druglik
characterist
first
step
process
understand
sar
carbohydr
lead
specif
contribut
made
function
group
bind
well
threedimension
present
pharmacophor
base
inform
possibl
identifi
glycomimet
preorgan
bioactiv
conform
adopt
bound
conform
solut
addit
mimic
show
improv
pharmacokinet
properti
particular
improv
bioavail
serum
halflif
minim
toxic
cost
synthesi
past
develop
carbohydratederiv
drug
often
entir
focus
simultan
solv
requir
highprofil
failur
result
notabl
field
selectin
antagonist
nevertheless
ration
design
glycomimet
potenti
reap
reward
rel
untap
sourc
novel
therapeut
widerang
import
biolog
medic
applic
understand
nativ
interact
start
point
ration
design
glycomimet
analysi
bind
characterist
binari
complex
threedimension
structur
lectin
complex
solv
number
therapeut
interest
target
thu
e
p
lselectin
cocrystal
slex
pselectin
glycoprotein
ligand
sialoadhesin
cocrystal
dcsign
cocrystal
pentasaccharid
ref
hold
valuabl
inform
ration
design
glycomimet
case
structur
yet
solv
homolog
model
gener
case
mag
detail
insight
bind
event
gain
nuclear
magnet
reson
nmr
experi
exampl
bound
conform
function
carbohydr
ligand
crd
target
lectin
determin
use
transfer
nuclear
overhaus
effect
noe
addit
bind
epitop
identifi
satur
transfer
differ
nmr
spectroscopi
std
nmr
spectroscopi
techniqu
use
studi
interact
carbohydr
ligand
rotaviru
receptor
ref
anticarbohydr
tumourassoci
antibodi
ref
overal
transfer
noe
nmr
std
nmr
experi
allow
rapid
insight
bind
characterist
interact
replac
least
partial
xray
investig
timeconsum
map
bind
epitop
chemic
enhanc
bind
affin
gener
low
affin
interact
consequ
shallow
bind
site
lectin
lead
high
solvent
access
complex
form
hydrogen
bond
salt
bridg
owe
larg
offrat
koff
binari
complex
character
short
dissoci
halfliv
typic
rang
second
shown
selectin
physiolog
carbohydraterecogn
antibodi
slea
ref
mag
given
therapeut
applic
binari
complex
expect
rang
minut
hour
improv
koff
glycomimet
compound
mandatori
therapeut
often
mammalian
lectin
undergo
numer
direct
weak
interact
ligand
specif
exampl
interact
slex
eselectin
outlin
fig
consist
six
solventexpos
hydrogen
bridg
salt
bridg
produc
complex
one
possibl
approach
improv
affin
preorgan
antagonist
bioactiv
conform
compens
low
enthalp
contribut
reduc
entropi
cost
bind
eselectin
strategi
success
see
complex
fig
elucid
std
studi
glcnac
moieti
interact
bind
site
serv
sole
linker
posit
galactos
fucos
moieti
correct
spatial
orient
success
replac
noncarbohydr
addit
steric
repuls
deriv
properli
place
substitu
linker
moieti
improv
preorgan
core
result
affin
correspond
furthermor
preorgan
carboxyl
optim
well
reveal
cyclohexyl
lactic
acid
best
mimic
target
lectin
offer
wellstructur
bind
pocket
free
energi
bind
improv
incorpor
addit
enthalp
contribut
success
exampl
neuraminidas
inhibitor
influenza
viral
coat
protein
neuraminidas
natur
substrat
correspond
glycal
compound
mimic
transit
state
hydrolyt
reaction
millimolar
micromolar
affin
improv
affin
transit
state
analogu
zanamivir
oseltamivir
result
guanidinium
substitut
posit
enabl
format
new
salt
replac
glycerol
side
chain
posit
lead
new
favour
lipophil
interact
induc
fig
final
multival
frequent
occur
natur
lead
tight
bind
situat
unival
bind
recognit
carbohydr
ligand
bacteri
mammalian
lectin
exampl
phenomenon
specif
inhibit
recognit
event
oligoval
ligand
propos
see
exampl
fig
howev
design
tightbind
oligoval
ligand
part
empir
endeavour
tailor
oligoval
wherebi
space
limit
number
tether
branch
match
adjac
sugar
bind
site
protein
protein
cluster
potenti
offer
substanti
increas
avid
pharmacokinet
unfortun
limit
pharmacokinet
data
report
carbohydr
glycomimet
oral
absorpt
passiv
permeat
membran
barrier
small
limit
regard
molecular
mass
polar
number
hydrogen
bridg
donor
hydrophil
natur
oligosaccharid
caus
larg
number
hydroxyl
group
charg
sulphat
carboxyl
make
oral
avail
virtual
imposs
therefor
glycomimet
design
pharmacokinet
well
pharmacodynam
profil
adjust
possibl
strategi
improv
passiv
absorpt
bioisoter
replac
crucial
prodrug
success
exampl
prodrug
approach
oseltamivir
ester
prodrug
absorb
ester
metabol
correspond
carboxyl
activ
metabolit
ref
absolut
bioavailabl
oral
administ
prodrug
detect
plasma
within
minut
reach
maxim
concentr
addit
feasibl
use
activetransport
system
abund
intestin
liver
kidney
brain
also
mani
drug
ration
design
deriv
natur
product
absorb
passiv
transport
antibiot
heart
glycosid
fungicid
take
advantag
activ
transport
addit
activ
transport
enforc
ration
design
exampl
incorpor
amino
acid
structur
therebi
creat
substrat
activ
transport
peptid
transport
also
known
also
known
success
exampl
valacyclovir
valtrexzelitrex
glaxosmithklin
antivir
drug
use
manag
herp
simplex
valin
attach
parent
drug
acyclovir
zovirax
glaxosmithklinebiovail
lead
fivefold
increas
oral
extens
analysi
structur
requir
transport
identifi
numer
analogu
higher
affin
valin
inform
valuabl
improv
oral
avail
usual
short
serum
halflif
rapid
excret
carbohydr
present
addit
challeng
design
glycomimet
drug
degrad
presenc
serum
liver
microsom
routin
assay
metabol
stabil
must
incorpor
earli
design
process
organ
anion
cation
transport
system
locat
liver
kidney
respons
activ
excret
organ
anion
transport
famili
recogn
anion
specif
carboxyl
group
connect
hydrophob
ring
structur
activ
metabolit
form
oseltamivir
exampl
glycomimet
drug
serum
halflif
diminish
recognit
remov
oat
probenecid
competit
inhibitor
administ
combin
oseltamivir
serum
halflif
activ
metabolit
strategi
suggest
extend
suppli
us
govern
stockpil
oseltamivir
case
nation
emerg
respons
pandem
outbreak
influenza
interact
probenecid
specif
transport
assay
examin
earli
develop
glycomimet
contain
charg
group
identifi
structur
element
may
advers
affect
serum
halflif
conclus
recent
effort
elucid
complex
function
human
glycom
pool
resourc
technolog
among
academ
centr
led
rapid
influx
discoveri
acknowledg
new
sourc
structur
inform
appar
human
genom
effort
drug
discoveri
review
show
challeng
medicin
chemistri
need
met
develop
druglik
glycomimet
past
effort
field
highlight
drawback
use
nativ
oligosaccharid
drug
typic
pharmacodynam
pharmacokinet
properti
insuffici
therapeut
applic
addit
lack
affin
suffer
low
tissu
permeabl
short
serum
halflif
poor
stabil
glycomimet
design
correct
shortcom
detail
insight
interact
requir
predominantli
provid
recent
progress
nmr
spectroscopi
xray
crystallographi
thu
identif
bound
conform
function
carbohydr
transfer
noe
nmr
allow
design
mimet
pharmacophor
preorgan
bioactiv
conform
lead
reduc
entropi
cost
upon
bind
incorpor
addit
bind
site
frequent
lead
hydrophob
contact
enhanc
affin
often
achiev
final
knowledg
bind
epitop
obtain
std
nmr
allow
identif
neglig
replac
function
group
consequ
design
glycomimet
improv
absorpt
distribut
metabol
excret
accomplish
current
principl
ration
design
glycomimet
implement
academ
institut
industri
laboratori
success
exampl
glycomimet
drug
emerg
strategi
develop
design
pave
way
realiz
potenti
rel
untap
sourc
therapeut
